GT Biopharma Inc
Change company Symbol lookup
Select an option...
GTBP GT Biopharma Inc
UNH UnitedHealth Group Inc
BAC Bank of America Corp
WSO Watsco Inc
LITB LightInTheBox Holding Co Ltd
CVCY Central Valley Community Bancorp
AFAQU AF Acquisition Corp
HCIIW Hudson Executive Investment Equity II Warrant Exp 31 Jan 2027 *W EXP 01/31/2027
MEDS TRxADE Health Inc
HCICW Hennessy Capital Investment V Equity Warrant Exp 15 Jan 2025 *W EXP 01/15/2025
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

Closing Price
$2.47
Day's Change
0.41 (19.90%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.48
Day's Low
2.10
Volume
(Average)
Volume:
171,097

10-day average volume:
170,736
171,097

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.